Amneal Pharmaceuticals, Inc.
AMRX
$11.96
-$0.16-1.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.02B | 2.93B | 2.85B | 2.83B | 2.79B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.02B | 2.93B | 2.85B | 2.83B | 2.79B |
| Cost of Revenue | 1.89B | 1.84B | 1.79B | 1.80B | 1.78B |
| Gross Profit | 1.13B | 1.09B | 1.07B | 1.03B | 1.01B |
| SG&A Expenses | 526.85M | 509.16M | 490.03M | 482.23M | 476.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.24M | -5.24M | -6.15M | -6.15M | -930.00K |
| Total Operating Expenses | 2.60B | 2.55B | 2.47B | 2.47B | 2.45B |
| Operating Income | 420.70M | 384.26M | 379.83M | 364.21M | 348.37M |
| Income Before Tax | 139.21M | 68.66M | 89.30M | 58.00M | -55.01M |
| Income Tax Expenses | 11.28M | 11.04M | 38.06M | 25.58M | 18.86M |
| Earnings from Continuing Operations | 127.93 | 57.62 | 51.24 | 32.42 | -73.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -55.88M | -51.72M | -47.87M | -45.47M | -43.01M |
| Net Income | 72.06M | 5.90M | 3.38M | -13.05M | -116.89M |
| EBIT | 420.70M | 384.26M | 379.83M | 364.21M | 348.37M |
| EBITDA | 644.27M | 624.74M | 625.19M | 605.03M | 584.56M |
| EPS Basic | 0.23 | 0.02 | 0.01 | -0.04 | -0.38 |
| Normalized Basic EPS | 0.21 | 0.07 | 0.02 | -0.05 | -0.07 |
| EPS Diluted | 0.23 | 0.02 | 0.01 | -0.04 | -0.38 |
| Normalized Diluted EPS | 0.21 | 0.07 | 0.01 | -0.05 | -0.07 |
| Average Basic Shares Outstanding | 1.25B | 1.25B | 1.24B | 1.24B | 1.24B |
| Average Diluted Shares Outstanding | 1.30B | 1.28B | 1.27B | 1.26B | 1.25B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |